Patients with secondary progressive multiple sclerosis (MS) may not benefit from treatment with IV immunoglobulin G (IVIG)

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1457, 2004-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intrathecal triamcinolone is more beneficial than IV mitoxantrone for the treatment of chronic progressive multiple sclerosis (MS)

By  

Inpharma, Vol. 1, Iss. 1559, 2006-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Management of Secondary-Progressive Multiple Sclerosis

By Gavin Giovannoni  

CNS Drugs, Vol. 18, Iss. 10, 2004-01 ,pp. : 653-669

Adis International

Access to resources Recommend Favorite

Rituximab for Secondary Progressive Multiple Sclerosis: A Case Series

By Rommer Paulus S.   Patejdl Robert   Winkelmann Alexander   Benecke Reiner   Zettl Uwe K.  

CNS Drugs, Vol. 25, Iss. 7, 2011-07 ,pp. : 607-613

Adis International

Access to resources Recommend Favorite

Paclitaxel therapy is promising in secondary progressive multiple sclerosis

By  

Inpharma, Vol. 1, Iss. 1227, 2000-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Stress, Depression and Antidepressant Treatment Options in Patients Suffering from Multiple Sclerosis

By  

Current Pharmaceutical Design, Vol. 18, Iss. 36, 2012-12 ,pp. : 5837-5845

Bentham Science Publishers

Access to resources Recommend Favorite